Ovarian cancer is a lethal gynaecological malignancy that affects over 295,000 women globally, with a 20% survival rate for advanced stage. Often diagnosed at a late stage, due to the non-specific nature of symptoms, detection of ovarian cancer at an early stage is paramount. The discovery of novel hormones and influencers of the tumour microenvironment provide a promising avenue of research for the identification of cancer biomarkers. This project aims to expand research of a novel glucogenic hormone within the tumour microenvironment using traditional mono-layer tissue culture techniques as well as 3D co-culture organ-on-a-chip technology in addition to clinical liquid biopsies in order to advance the molecular understanding of ovarian cancer aetiology.
Meet the Principal Investigator(s) for the project
Dr Emmanouil Karteris - Dr Manos Karteris graduated with a BSc (Hons) in Medical Biochemistry from the University of Surrey in 1995. He then was awarded an MSc with Distinction in Medical Genetics with Immunology from Â鶹¹û¶³´«Ã½University London in 1996 and completed his PhD in Molecular Endocrinology from the University of Warwick in 2000. He then undertook post-doctoral appointments at the University of Warwick, including a prestigious VIP Research Fellowship from the Wellcome Trust. He was appointed as Lecturer in Endocrinology at the University of Warwick from 2005-2006 and then he transferred to Â鶹¹û¶³´«Ã½University London as a Lecturer in Biomedical Sciences in June 2006. Currently he is a Reader in the Division of Biomedical Sciences. Dr Karteris is the Departmental Director International.
Related Research Group(s)
Organ-on-a-Chip - The group’s main research focus is on women’s health and developing four main organ-on-a-chip (OOC) models: the breast, vagina, ovary, and placenta.
Partnering with confidence
Organisations interested in our research can partner with us with confidence backed by an external and independent benchmark: The Knowledge Exchange Framework. Read more.
Project last modified 21/11/2023